Saturday, December 08, 2018 2:29:49 PM
. The timing of Q3 2019 is interesting. The initial 199m2 is not a significant size but the initial licensing is the most difficult for a new enterprise. The expansion capability of addl 7500m2 is significant and they will want to begin the next phase as soon as possible. The additions will have been planned in phases and in a way that interruption to current operations is quite minimal. They are doing the right things and just need financing to keep moving in lockstep with expected approvals.
DoingMyBest is uniquely professionally qualified to make the above statement.
Thanks for confirming my own thoughts on the matter which was prompted by GREAT SLEUTHING and commentary on numerous wide ranging fronts from Longfellow!
Everyone should then be assembling the following underlayments recently:
1) the 2nd “bridge loan financing by Bigger Capital et al(prompted by the updated “proof of concept with DCVax L)
2)the possible exercising of 22 cts options ( 25 CT’s options later)by “friends of CEO Linda Powers” given the short time window for the above critical mfg expansion deployment as one of the necessary prerequisites for regulatory approval
3)BSB’s strong assertions a deal amongst the parties that CEO Linda Powers is negotiating upon.
4)Whether it be unblinding or regulatory approval THE PRICE for doing a transaction with NWBO’s CEO Linda Powers goes up exponentially. So the pressure is applied more towards buyers since NWBO should be in the cat’s bird seat based on recent developments above! iMHO
5)Furthermore, CEO Linda Powers may not accept what she feels as unreasonable from a valuation perspective whether it be licensing or partnership.... sellout. Each one of those three entails a progressively HIGHER quantum jump in higher hurdles! that needs agreements on both sides.
So the rafter of commentaries will waffle all over the map depending on:
1)your cost per share and
2)one’s reaction to CEO’s clandestine communiques or even
3)raping shareholders with her recent amended options plan.
4)upsetting all those watchers on the scientific front. CEO Linda Powers DID state that the longer the trial takes to the end... The BETTER the results!
UNLESS you really know what cards she’s holding back or what cards her parties she’s been negotiating with has revealed ...... it’s Hocus Pocus!
[All I know is that her interests as the control party are totally aligned with long term shareholders!
This has been a long and frustrating investment journey for those investing even for those for but
the last 18 months and very few have shown the mental tenacity and diversity necessary to have upwards of 40% appreciation.
The emotional side on this MB shows here in SPADES!
Flipper: I did anticipate Cognate being sold to allow her personal funding flexibility and remove a going forward investment albatrosses she endeavors to rise up from the ashes TWICE to her deserved Phoenix and have institutional ownership and respect!
For those still stuck on BlackRock: likely you are wrong is 90%. BlackRock to my knowledge doesn’t’ have Venture Capital funds they manage. Given t CEO’s Fink’s and executive mgt staff backgrounds.... BlackRock are strictly financiers.
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
